Psoriasis and infection. A clinical practice narrative
M Rademaker, K Agnew, N Anagnostou… - Australasian Journal …, 2019 - Wiley Online Library
Abstract The Australasian Psoriasis Collaboration has developed a clinical practice
narrative with respect to the relationship between psoriasis, its treatment and infection. The …
narrative with respect to the relationship between psoriasis, its treatment and infection. The …
Liver illness and psoriatic patients
Psoriasis is a chronic inflammatory disease of the skin affecting approximately 2% of the
world's population. Systemic treatments, including methotrexate and cyclosporin, are …
world's population. Systemic treatments, including methotrexate and cyclosporin, are …
Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian …
JLW Lambert, S Segaert, PD Ghislain… - Journal of the …, 2020 - Wiley Online Library
Background Psoriasis patients carry an increased risk for associated comorbidities.
Dermatologists have to be aware of the effects of systemic treatments not only on psoriasis …
Dermatologists have to be aware of the effects of systemic treatments not only on psoriasis …
[PDF][PDF] S3‐Leitlinie zur Therapie der Psoriasis vulgaris Update 2011
A Nast, WH Boehncke, U Mrowietz… - JDDG: Journal der …, 2011 - psoriasis-rheinruhr.de
1.1 Bedarfsanalyse/Probleme in der Versorgung der Patienten Die Psoriasis vulgaris stellt
eine häufige und fast immer chronisch verlaufende dermatologische Erkrankung dar. Die …
eine häufige und fast immer chronisch verlaufende dermatologische Erkrankung dar. Die …
Managing psoriasis in patients with HBV or HCV infection: practical considerations
S Piaserico, F Messina, FP Russo - American Journal of Clinical …, 2019 - Springer
Considered more efficacious and safer than traditional systemic drugs, biologic therapies
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …
[PDF][PDF] TNF inhibitors for psoriasis
M Chima, M Lebwohl - Semin Cutan Med Surg, 2018 - scmsjournal.com
■ Abstract Tumor necrosis factor (TNF)-α has been identified as a key cytokine mediating
cutaneous inflammation in the pathogenesis of psoriasis. The TNF inhibitors (TNFi's) …
cutaneous inflammation in the pathogenesis of psoriasis. The TNF inhibitors (TNFi's) …
[HTML][HTML] Treatment of psoriasis with secukinumab in challenging patient scenarios: a review of the available evidence
JJ Wu, JF Merola, SR Feldman, A Menter… - Dermatology and …, 2020 - Springer
Psoriasis (PsO) is a common, systemic, chronic, inflammatory disease characterized by key
clinical symptoms, including itching, pain, and scaling. PsO is associated with a high …
clinical symptoms, including itching, pain, and scaling. PsO is associated with a high …
INASL guidelines on management of hepatitis B virus infection in patients receiving chemotherapy, biologicals, immunosupressants, or corticosteroids
Hepatitis B Virus (HBV) reactivation in patients receiving chemotherapy, biologicals,
immunosupressants, or corticosteroids is emerging to be an important cause of morbidity …
immunosupressants, or corticosteroids is emerging to be an important cause of morbidity …
[HTML][HTML] Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID‑19
The cytokine storm from the evolution of severe cases of COVID‑19, requiring strong
immunosuppressive therapies, has raised the issue of reactivation of hepatitis B virus (HBV) …
immunosuppressive therapies, has raised the issue of reactivation of hepatitis B virus (HBV) …
[HTML][HTML] Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct …
G Damiani, C Franchi, P Pigatto… - World Journal of …, 2018 - ncbi.nlm.nih.gov
AIM To evaluate the outcomes in biological treatment and quality of life of psoriatic patients
with chronic hepatitis C (CHC) treated with new Direct-Acting Antiviral agents (DAAs) …
with chronic hepatitis C (CHC) treated with new Direct-Acting Antiviral agents (DAAs) …